Supplements Manufacturer retweetledi
Supplements Manufacturer
8.7K posts
Supplements Manufacturer
@MoreFlax
We formulate, process and pack private label products. Our herbal, vitamins, protein, collagen, and fiber based products are distributed nationally. Powders #1.
🟥⬛⬛⬛🟥 BJJ Katılım Temmuz 2022
5.1K Takip Edilen1.6K Takipçiler
$OCGN #OCUGEN @Ocugen @drsmusunuri 👇 ♥️ ❤️
"raising our price target to $12 per share"
channelchek.com/news-channel/o…
English
$OCGN #OCUGEN 👇 👇 👇
Ocugen Inc (OCGN) Stock Forecast, Price Targets and Analysts Predictions - TipRanks.com share.google/IRX7GEdbc2GfE0…
English
Supplements Manufacturer retweetledi
$ocgn just showed they have the new standard of care for GA, phase 3 starts this year, market dumps early retail panics, everyone worrying about results that point to the next standard of care…
Next OCU410ST Pivotal 2/3 announces enrollment completion, another blockbuster clock starts, this one comes with a PRV on approval which will be worth around $200-$250 million.
OCU400 rolling BLA starts, will target 99% of the RP market and Ocugen will transform from a pre revenue bio to a leader in gene therapy’s.
You can choose to focus on the day to day noise, worry about the volatility and question what you own. Or you can focus on the facts, capitalize and enjoy knowing you own the next pharmaceutical giant before the rest of the world catches on. No 🧠’er 🍻 🐂
English
Supplements Manufacturer retweetledi
Exciting Phase 2 results and a clear path to Phase 3 for GA.
English
$OCGN #OCUGEN @Ocugen @drsmusunuri @drhumaqamar
Great results.... congratulations!!!
Thank you for all of your efforts!
Ocugen@Ocugen
Today, CEO @drsmusunuri shares encouraging 12-month Phase 2 results for #OCU410 in GA, showing impact on lesion growth and visual function. A one-time gene therapy approach with potential to shift the landscape and address unmet needs. Read more: bit.ly/4lLGXYV
English
Supplements Manufacturer retweetledi
Today, CEO @drsmusunuri shares encouraging 12-month Phase 2 results for #OCU410 in GA, showing impact on lesion growth and visual function. A one-time gene therapy approach with potential to shift the landscape and address unmet needs.
Read more: bit.ly/4lLGXYV
English
$OCGN #OCUGEN 👇 👇 👇
Wait till the call, let the doctors present and clear few things up.
All good!
English
Supplements Manufacturer retweetledi
Live Webcast Phase 2 ArMaDa trial on 3/24
Ocugen@Ocugen
Ocugen will host a live webcast Mar 24 at 8 a.m. EDT on Phase 2 ArMaDa data for #OCU410 in GA, led by KOLs Lejla Vajzovic, MD, and Jay Chhablani, MD. Don’t miss key insights into advancements in modifier gene therapy for retinal disease. Details: bit.ly/4uJ8GgG
English
$OCGN #OCUGEN 👇 👇 👇 👇
Why would you have top doctors in a field on a conference call unless it's really good data to present!!!
🤫🤫🤫
English
Supplements Manufacturer retweetledi
Ocugen will host a live webcast Mar 24 at 8 a.m. EDT on Phase 2 ArMaDa data for #OCU410 in GA, led by KOLs Lejla Vajzovic, MD, and Jay Chhablani, MD. Don’t miss key insights into advancements in modifier gene therapy for retinal disease.
Details: bit.ly/4uJ8GgG
English
Supplements Manufacturer retweetledi
$ocgn quad witching, they do this every time and kill the calls. Big data comes out within the next two weeks. Gonna be a green Monday. 🍻
English
Supplements Manufacturer retweetledi
$OCGN Funding Announcement:
On March 12, 2026, Ocugen, Inc. reported that an institutional investor purchased 10,000,000 shares of common stock for $15 million after partially exercising their warrants, extending the company's cash runway into Q1 2027.
stockinsights.ai/us/OCGN/8-K/ca…
English